A new treatment for post-transplant leukemia relapse! A study by José Cohen’s I-BIOT team published this month in the Journal for Immunotherapy of cancer
Leukemia is a group of several types of blood cancer that affect up to 10,000 people in France each year. One of the proposed treatments is the transplant of hematopoietic stem cells. These cells are produced by the bone marrow and are the source of the various blood cells. Despite the success of this therapeutic approach, which allows cancerous cells to be replaced by healthy cells, approximately 30% of patients will relapse after the transplant.
In a new study, researchers from the IMRB (I-BIOT) of the UPEC Faculty of Health in collaboration with researchers from Inserm and AP-HP have identified a new target to treat post hematopoietic stem cell transplant leukemia relapses by the simple use of a therapeutic antibody. These results are published in the Journal for Immunotherapy of cancer in April.